title: Review of the safety and feasibility of rapid infusion of rituximab.
abstract: Added to standard chemotherapy, rituximab improved survival in patients with non-Hodgkin's lymphoma; added to fludarabine-based regimens, it improved response and survival in patients with chronic B-cell lymphocytic leukemia.
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX.
authors.forename: Jill
authors.initials: J
authors.lastname: Atmar